NCT05645380 - Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions

Triple Negative Breast CancerBreast Cancer

Interventions

DRUG

Carboplatin

AUC=6, IV

DRUG

Docetaxel

75 mg/m2, IV

DRUG

Doxorubicin

60 mg/m2, IV

DRUG

Cyclophosphamide

600 mg/m2, IV

DRUG

Pembrolizumab

200 mg, IV

Trial Locations (7)

64064

RECRUITING

The University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64116

RECRUITING

University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City

64154

RECRUITING

The University of Kansas Cancer Center - North, Kansas City

66160

RECRUITING

The University of Kansas Cancer Center - Main Hospital, Kansas City

66205

RECRUITING

The University of Kansas Cancer Center - Clinical Research Center, Fairway

RECRUITING

The University of Kansas Cancer Center - Westwood, Kansas City

66210

RECRUITING

The University of Kansas Cancer Center - Overland Park, Overland Park

All Listed Sponsors

lead

University of Kansas Medical Center

OTHER